Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis (65%), asthma (20%), and CRSwNP (10%) as core indications; each faces varying competitive pressures. Revenue projections for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results